Immunizations could be administered within minutes where and when a disease is breaking out.
Vaccines combat diseases and protect populations from outbreaks, but the life-saving technology leaves room for improvement. Vaccines usually are made en masse in centralized locations far removed from where they will be used. They are expensive to ship and keep refrigerated and they tend to have short shelf lives.
University of Washington engineers hope a new type of vaccine they have shown to work in mice will one day make it cheaper and easy to manufacture on-demand vaccines for humans. Immunizations could be administered within minutes where and when a disease is breaking out.
“We’re really excited about this technology because it makes it possible to produce a vaccine on the spot. For instance, a field doctor could see the beginnings of an epidemic, make vaccine doses right away, and blanket vaccinate the entire population in the affected area to prevent the spread of an epidemic,” said François Baneyx, a UW professor of chemical engineering and lead author of a recent paper published online in the journal Nanomedicine.
In typical vaccines, weakened pathogens or proteins found on the surface of microbes and viruses are injected into the body along with compounds called adjuvants to prepare a person’s immune system to fight a particular disease. But standard formulations don’t always work, and the field is seeking ways to manufacture vaccines quicker, cheaper and tailored to specific infectious agents, Baneyx said.
The UW team injected mice with nanoparticles synthesized using an engineered protein that both mimics the effect of an infection and binds to calcium phosphate, the inorganic compound found in teeth and bones. After eight months, mice that contracted the disease made threefold the number of protective “killer” T-cells – a sign of a long-lasting immune response – compared with mice that had received the protein but no calcium phosphate nanoparticles.
The nanoparticles appear to work by ferrying the protein to the lymph nodes where they have a higher chance of meeting dendritic cells, a type of immune cell that is scarce in the skin and muscles, but plays a key role in activating strong immune responses.
In a real-life scenario, genetically engineered proteins based on those displayed at the surface of pathogens would be freeze-dried or dehydrated and mixed with water, calcium and phosphate to make the nanoparticles. This should work with many different diseases and be especially useful for viral infections that are hard to vaccinate against, Baneyx said.
He cautioned, however, that it has only been proven in mice, and the development of vaccines using this method hasn’t begun for humans.
The Latest on: On-demand vaccines
via Google News
The Latest on: On-demand vaccines
- Israel’s COVID-19 Innovationon June 27, 2020 at 11:58 pm
CytoReason is now offering COVID-19 modeling to help pharma and biotech companies search for a cure – free of charge. The company has opened its software to all of its pharma customers worldwide, ...
- 'King of Staten Island' tests the grown-up appetite for digital movieson June 27, 2020 at 11:44 pm
The R-rated movie, which follows Davidson's life as a twenty-something who lost his firefighter father at a young age, was set to be the first major test of the "SNL" ...
- Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bedon June 19, 2020 at 3:43 pm
Autologous tumor cell–based vaccines (ATVs) are emerging as a transformable approach for personalized immunotherapy, but their therapeutic efficacy remains unsatisfying in patients with cancer. Here, ...
- Microsoft employs experimental undersea data center in search for COVID-19 vaccineon June 17, 2020 at 7:13 am
Part of the challenge in seeking out an effective treatment for COVID-19 is simply one of scale — protein folding is key to understanding how the virus that causes COVID-19 attaches to health cells in ...
- U.S. Departments of Defense, Health & Human Services select Corning Valor(R) Glass packaging to accelerate delivery of COVID-19 vaccineson June 9, 2020 at 5:30 am
CORNING, NY, June 09, 2020 (GLOBE NEWSWIRE) -- Corning Incorporated (NYSE: GLW) today announced it will receive $204 million from the Biomedical Advanced Research and Development Authority (BARDA), ...
- What innovations do people actually need after the pandemic? Not flying cars.on June 4, 2020 at 2:06 pm
Why can’t we mobilize, he wondered sensibly, the production of on-demand vaccines and protective equipment? It is hard not to feel the allure of flying in a car—it is, after all, socially ...
- Press Launch of hVIVO COVID Clear Test, the Most Accurate Antibody Test Available to UK Employers to Help Get People Back to Workon June 3, 2020 at 11:32 pm
This is the first time that such on demand testing is made available to ... hVIVO, the world leader in the testing of vaccines and antivirals through human challenge study clinical trials, is ...
- Press Launch of hVIVO COVID Clear Test, the Most Accurate Antibody Test Available to UK Employers to Help Get People Back to Workon June 3, 2020 at 11:17 pm
This is the first time that such on demand testing is made available to large employer ... hVIVO, the world leader in the testing of vaccines and antivirals through human challenge study clinical ...
- Vaccines for the treatment and prevention of canceron June 3, 2020 at 1:00 am
Cancer vaccines are increasingly being developed and tested as a cancer treatment and prevention strategy ... Webinars will be available for unlimited on-demand viewing after live event. LabRoots is ...
- Will a COVID-19 vaccine arrive by 2021? Health tech leaders are skepticalon June 1, 2020 at 5:45 am
But according to a recent survey by VC firm Venrock, they are excited about the future of telemedicine and big health data.
via Bing News